A citation-based method for searching scientific literature

Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
Times Cited: 405







List of co-cited articles
1203 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
51

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
756
32

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
32

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
928
26

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
656
24

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
23

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
391
21

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
21

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
19

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
421
19

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
462
18

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans,[...]. J Am Coll Cardiol 2009
350
17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
17

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
310
17

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
16


Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Kenneth B Margulies, Adrian F Hernandez, Margaret M Redfield, Michael M Givertz, Guilherme H Oliveira, Robert Cole, Douglas L Mann, David J Whellan, Michael S Kiernan, G Michael Felker,[...]. JAMA 2016
310
15

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen,[...]. Eur J Heart Fail 2017
214
15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
15

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
166
15

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
490
14

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.
John R Ussher, Laurie L Baggio, Jonathan E Campbell, Erin E Mulvihill, Minsuk Kim, M Golam Kabir, Xiemin Cao, Benjamin M Baranek, Doris A Stoffers, Randy J Seeley,[...]. Mol Metab 2014
82
17

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
247
14

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
258
14


GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Naim Panjwani, Erin E Mulvihill, Christine Longuet, Bernardo Yusta, Jonathan E Campbell, Theodore J Brown, Catherine Streutker, Dianne Holland, Xiemin Cao, Laurie L Baggio,[...]. Endocrinology 2013
237
13

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
273
13

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
730
13

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
393
12

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
12

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
848
12

Cardiovascular biology of the incretin system.
John R Ussher, Daniel J Drucker. Endocr Rev 2012
376
11

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Tingcun Zhao, Pratik Parikh, Siva Bhashyam, Hakki Bolukoglu, Indu Poornima, You-Tang Shen, Richard P Shannon. J Pharmacol Exp Ther 2006
235
11


Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
502
11


Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Kiwon Ban, Kyoung-Han Kim, Chan-Kyung Cho, Meghan Sauvé, Eleftherios P Diamandis, Peter H Backx, Daniel J Drucker, Mansoor Husain. Endocrinology 2010
164
11

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
Wei-Ren Chen, Xue-Qin Shen, Ying Zhang, Yun-Dai Chen, Shun-Ying Hu, Geng Qian, Jing Wang, Jun-Jie Yang, Zhi-Feng Wang, Feng Tian. Endocrine 2016
49
20

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
511
10

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Jacob Lønborg, Henning Kelbæk, Niels Vejlstrup, Hans Erik Bøtker, Won Yong Kim, Lene Holmvang, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Christian Juhl Terkelsen,[...]. Circ Cardiovasc Interv 2012
160
10

GLP-1 Receptor Expression Within the Human Heart.
Laurie L Baggio, Bernardo Yusta, Erin E Mulvihill, Xiemin Cao, Catherine J Streutker, Jagdish Butany, Thomas P Cappola, Kenneth B Margulies, Daniel J Drucker. Endocrinology 2018
105
10

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
10

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
10

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
521
10

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
Paulus Wohlfart, Wolfgang Linz, Thomas Hübschle, Dominik Linz, Jochen Huber, Sibylle Hess, Daniel Crowther, Ulrich Werner, Hartmut Ruetten. J Transl Med 2013
52
17


Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, You-Tang Shen, Richard P Shannon. Am J Physiol Heart Circ Physiol 2005
209
9

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Yumei Ye, Kyle T Keyes, Congfang Zhang, Jose R Perez-Polo, Yu Lin, Yochai Birnbaum. Am J Physiol Heart Circ Physiol 2010
130
9




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.